Close up picture of microscope in the laboratory
Our Work

Latham & Watkins Advises Zentalis in Exclusive License With Immunome for ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

January 8, 2024
The firm represents the clinical-stage biopharmaceutical company in the transaction.

Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), have announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate (ADC) with best-in-class potential on track for IND submission in 1Q 2025, and Zentalis’ proprietary ADC platform technology.

Latham & Watkins LLP advised Zentalis in the transaction with a licensing team led by New York partner Aaron Gardner, with San Diego associate Robert Yeh, and a corporate team led by New York partners Nathan Ajiashvili and Salvatore Vanchieri, with associate Matthew DeSilva.